CEL-SCI Corporation
AMEXCEL-SCI Corporation has just gone through one of the most violent short-interest cycles seen in a micro-cap biotech this year — and with earnings four days away, the dust is far from settled. The short side of CVM exploded in early May. Short interest as a percentage of free float climbed from around 10% at the end of April to a peak of 50% on May 12 — a fivefold build…
CVM cost to borrow soars to 625% — up 846% in one week as short interest hits 49% of float.
CEL-SCI Corporation has just gone through one of the most violent short-interest cycles seen in a micro-cap biotech this year — and with earnings four days away, the dust is far from settled. The short side of CVM…
CEL-SCI Corporation has entered a critical borrow squeeze. Short interest, cost to borrow, and availability have all moved to extreme levels simultaneously — with an earnings event tomorrow acting as the catalyst…
Snapshot as of 22 Jun 2026
CEL-SCI Corporation heads into its May 13 earnings print with one of the most aggressive short-selling buildups in the small-cap biotech space right now. The lending market tells the sharpest story. Cost to borrow has…
CEL-SCI Corporation is heading into its May 13 earnings with short sellers rebuilding aggressively — and the stock at its weakest price in months. Short interest has nearly doubled in a week. SI % FF climbed from…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CVM — free to start on ORTEX.
Sign up for free →Open CVM on ORTEX